- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02184442
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B (PARTNERII B)
The PARTNER II Trial "Placement of AoRTic TraNscathetER" Valves Trial" (US) [PII B] for Inoperable Patients
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Cohort B was a 1:1 randomized, controlled study independently powered to compare transcatheter heart valve therapy with the first generation (SAPIEN™ THV) system to transcatheter heart valve therapy with the second generation (SAPIEN XT THV) system in patients who could not undergo surgery (inoperable).
Patients in the control arm of Cohort B received an Edwards SAPIEN THV with the associated delivery system while patients in the treatment arm of Cohort B received an Edwards SAPIEN XT THV with the associated delivery system.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72211
- Arkansas Heart Hospital/Clinic
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- Scripps Green Hospital
-
La Jolla, California, Estados Unidos, 92037
- Scripps Memorial Hospital
-
Los Angeles, California, Estados Unidos, 90048
- Cedars-Sinai Medical Center
-
Sacramento, California, Estados Unidos, 95816
- Mercy General Hospital
-
Stanford, California, Estados Unidos, 94305
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80045
- University of Colorado Hospital
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20010
- Washington Hospital Center (WHC)
-
-
Florida
-
Clearwater, Florida, Estados Unidos, 33756
- Morton Plant Hospital
-
Gainesville, Florida, Estados Unidos, 32610
- University of Florida, Gainesville
-
Miami, Florida, Estados Unidos, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Emory University Hospital
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush University Medical Center
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern Hospital
-
Springfield, Illinois, Estados Unidos, 62701
- Prairie Education And Research Cooperative
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University Health-Methodist Hospital
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- The University of Iowa
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- University of Louisville - Jewish Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- University of Maryland Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
Royal Oak, Michigan, Estados Unidos, 48073
- William Beaumont Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Minneapolis Heart Institute Foundation
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Saint Luke's Hospital of Kansas City Mid America
-
Saint Louis, Missouri, Estados Unidos, 63110
- Washington University - Barnes Jewish Hospital
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68526
- Nebraska Heart Institute
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Newark, New Jersey, Estados Unidos, 07112
- Newark Beth Israel
-
-
New York
-
Manhasset, New York, Estados Unidos, 11030
- North Shore University Hospital, NY
-
Mineola, New York, Estados Unidos, 11501
- Winthrop University Hospital
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center
-
New York, New York, Estados Unidos, 10021
- Cornell University
-
-
North Carolina
-
Charleston, North Carolina, Estados Unidos, 29425
- Medical University of South Carolina Charleston
-
Greenville, North Carolina, Estados Unidos, 27834
- East Carolina Heart Institute at East Carolina University
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- The Christ Hospital, Cincinnati
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Foundation
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73135
- Oklahoma Heart Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania Hospital
-
York, Pennsylvania, Estados Unidos, 17403
- York Hospital
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38120
- Baptist Memorial Hospital
-
-
Texas
-
Austin, Texas, Estados Unidos, 78756
- Austin Heart, PLLC
-
Dallas, Texas, Estados Unidos, 75230
- Medical City Dallas Hospital
-
Dallas, Texas, Estados Unidos, 75093
- The Heart Hospital Baylor Plano
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas Health Science Center at Houston/Memorial Hermann Texas Medical Center
-
San Antonio, Texas, Estados Unidos, 78229-3900
- University of Texas Health Science Center at San Antonio (UTHSCSA)
-
-
Utah
-
Murray, Utah, Estados Unidos, 84157
- Intermountain Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22904
- University of Virginia
-
Norfolk, Virginia, Estados Unidos, 23507
- Sentara Norfolk General Hospital
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- University of Washington
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin - Madison
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
- Patient was symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class II or greater.
- The probability of death or serious, irreversible morbidity is greater than or equal to 50%.
- The heart team agreed (and verified in the case review process) that valve implantation would likely benefit the patient.
- The study patient or the study patient's legal representative was informed of the nature of the study, agreed to its provisions and had provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
- The study patient agreed to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which was conducted as a phone follow-up.
Exclusion Criteria
- Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.
- Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta. (Transfemoral)
- Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- It is known that the patient is currently enrolled in the PARTNER I Trial or was withdrawn from the PARTNER I Trial prior to endpoint analysis.
- Active bacterial endocarditis within 6 months (180 days) of procedure.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: TAVR - SAPIEN XT
TAVR (transaortic valve replacement) with SAPIEN XT
|
Inoperable operable patients requiring the transcatheter aortic heart valve replacement
|
|
Comparador Ativo: TAVR - SAPIEN
TAVR (transaortic valve replacement) with SAPIEN is the control arm
|
Inoperable operable patients requiring the transcatheter aortic heart valve replacement
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With All-Cause Mortality and/or Major Stroke and/or Rehospitalization
Prazo: 1 Year
|
All-Cause Mortality and/or Major Stroke and/or Rehospitalization at 1 Year
|
1 Year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
NYHA Classification - Change From Baseline
Prazo: Baseline and 1 Year
|
New York Heart Association (NYHA), functional classification of heart failure based on how much a patient is limited during physical activity.
The rating ranges from I - IV, with the lowest as no limitations and the highest unable to carry on any physical activity without discomfort.
|
Baseline and 1 Year
|
|
Total Aortic Regurgitation - Change From Baseline
Prazo: 1 Year
|
Total aortic regurgitation was assessed by the core lab as 'Grade 0' = None, 'Grade 1+' = Trace, 'Grade 2+' = Mild, 'Grade 3+' = Moderate, and 'Grade 4+' = Severe. Total regurgitation at one year was analyzed in the valve implant population. |
1 Year
|
|
Effective Orifice Area - Change From Baseline
Prazo: 1 Year
|
1 Year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Martin B Leon, MD, Columbia University
Publicações e links úteis
Publicações Gerais
- Chen S, Redfors B, O'Neill BP, Clavel MA, Pibarot P, Elmariah S, Nazif T, Crowley A, Ben-Yehuda O, Finn MT, Alu MC, Vahl TP, Kodali S, Leon MB, Lindman BR. Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry. Eur Heart J. 2020 Feb 21;41(8):958-969. doi: 10.1093/eurheartj/ehz892.
- Summers MR, Leon MB, Smith CR, Kodali SK, Thourani VH, Herrmann HC, Makkar RR, Pibarot P, Webb JG, Leipsic J, Alu MC, Crowley A, Hahn RT, Kapadia SR, Tuzcu EM, Svensson L, Cremer PC, Jaber WA. Prosthetic Valve Endocarditis After TAVR and SAVR: Insights From the PARTNER Trials. Circulation. 2019 Dec 10;140(24):1984-1994. doi: 10.1161/CIRCULATIONAHA.119.041399. Epub 2019 Nov 6.
- Furer A, Chen S, Redfors B, Elmariah S, Pibarot P, Herrmann HC, Hahn RT, Kodali S, Thourani VH, Douglas PS, Alu MC, Fearon WF, Passeri J, Malaisrie SC, Crowley A, McAndrew T, Genereux P, Ben-Yehuda O, Leon MB, Burkhoff D. Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement: Analysis of the PARTNER 2 Trials. Circ Heart Fail. 2019 Aug;12(8):e005809. doi: 10.1161/CIRCHEARTFAILURE.118.005809. Epub 2019 Aug 1.
- Genereux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, Kapadia S, Thourani VH, Mack MJ, Nazif TM, Lindman BR, Babaliaros V, Vincent F, Russo M, McCabe JM, Gillam LD, Alu MC, Hahn RT, Webb JG, Leon MB, Cohen DJ. Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement. J Am Coll Cardiol. 2022 Aug 23;80(8):783-800. doi: 10.1016/j.jacc.2022.05.006. Epub 2022 May 17.
- Shahim B, Redfors B, Lindman BR, Chen S, Dahlen T, Nazif T, Kapadia S, Gertz ZM, Crowley AC, Li D, Thourani VH, Kodali SK, Zajarias A, Babaliaros VC, Guyton RA, Elmariah S, Herrmann HC, Cohen DJ, Mack MJ, Smith CR, Leon MB, George I. Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries. J Am Heart Assoc. 2022 Jun 7;11(11):e024091. doi: 10.1161/JAHA.121.024091. Epub 2022 Jun 3.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2010-12-PIIB
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .